Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration

NCT: NCT06381596 · COMPLETED

NCT IDNCT06381596
StatusCOMPLETED
Start Date2024-04-16
Completion2025-05-27
SponsorUniversity of Wisconsin, Madison (OTHER)
First posted
Last updated

Brief Summary

The goal of this clinical trial is to learn if the areas of stressed cells in the retina correlate to areas of disease identified in standard imaging and whether the images are helpful to identify potential areas of concern before symptoms or disease occurs. The main question it aims to answer is: * to evaluate patterns of increased autofluorescence FPF in the setting of geographic atrophy Participants will undergo FPF imaging using the OcuMet Beacon system.

Frequently Asked Questions

What is Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration?

Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration is a clinical trial registered under NCT06381596. Current status: COMPLETED.

What is the status of NCT06381596?

The current status of NCT06381596 (Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration) is: COMPLETED.

When did Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration start?

Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration started on 2024-04-16.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.